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Background: BRAF mutation is an important diagnostic and prognostic marker in patients with papillary thyroid
carcinoma (PTC). To be applicable in clinical laboratories with limited equipment, diverse testing methods are
required to detect BRAF mutation.
Methods: A shifted termination assay (STA) fragment analysis was used to detect common V600 BRAF mutations in
159 PTCs with DNAs extracted from formalin-fixed paraffin-embedded tumor tissue. The results of STA fragment
analysis were compared to those of direct sequencing. Serial dilutions of BRAF mutant cell line (SNU-790) were used
to calculate limit of detection (LOD).
Results: BRAF mutations were detected in 119 (74.8%) PTCs by STA fragment analysis. In direct sequencing, BRAF
mutations were observed in 118 (74.2%) cases. The results of STA fragment analysis had high correlation with those
of direct sequencing (p < 0.00001, κ = 0.98). The LOD of STA fragment analysis and direct sequencing was 6% and
12.5%, respectively. In PTCs with pT3/T4 stages, BRAF mutation was observed in 83.8% of cases. In pT1/T2
carcinomas, BRAF mutation was detected in 65.9% and this difference was statistically significant (p = 0.007).
Moreover, BRAF mutation was more frequent in PTCs with extrathyroidal invasion than tumors without
extrathyroidal invasion (84.7% versus 62.2%, p = 0.001). To prepare and run the reactions, direct sequencing required
450 minutes while STA fragment analysis needed 290 minutes.
Conclusions: STA fragment analysis is a simple and sensitive method to detect BRAF V600 mutations in formalin-
fixed paraffin-embedded clinical samples.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/5684057089135749
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BRAF is a serine/threonine kinase that functions as a
part of the RAS/RAF/MEK /ERK/MAPK pathway, which
is involved in the transduction of mitogenic signals from
the cell membrane to the nucleus. A single hotspot mu-
tation at nucleotide 1799 of BRAF gene has been identi-
fied as the most common genetic event in papillary* Correspondence: bijou@skku.edu; kkmkys@skku.edu
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reproduction in any medium, provided the orthyroid carcinoma (PTC) with a prevalence of 29–83% [1].
Recently, systematic review and meta-analyses on PTC
showed that BRAF mutation is significantly associated
with recurrence, lymph node metastasis, extrathyroidal ex-
tension and advanced tumor stages [2-4]. So far, detection
of this mutation has been achieved by co-amplification at
lower denaturation temperature (COLD)-PCR, allele-
specific polymerase chain reaction (AS-PCR), high-
resolution melting curve (HRM) analysis, SNaPshot Assay,
pyrosequencing and direct sequencing. Each technique
has advantages and limitations with regard to cost, avai-
lability, and enrichment efficiency.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for the determination of mutations in formalin-fixed,
paraffin-embedded (FFPE) tissue samples although this
technique is time consuming, expensive [5,6] and the
sensitivity is relatively low [7,8]. A key limitation of
PCR-based methods in the detection of BRAF mutations
is the inability to selectively amplify low percentages of
variant alleles from a wild-type allele background [9]. In
this study, we first applied shifted termination assay
(STA) fragment analysis to detect the common hot-spot
BRAF mutation in 159 PTCs and compared the results
to those of direct sequencing using DNAs from FFPE
tissue samples consisting of 53 tumors less than 0.5 cm
in size.
Materials and methods
Patients and tumor samples
One hundred and fifty nine PTCs were randomly re-
trieved from the surgical pathology files of Samsung
Medical Center, Seoul, Korea between 2010 and 2011.
The study was approved by the Institutional Review
Board of the Samsung Medical Center (IRB #2009-09-
010). The informed consent was obtained from the pa-
tient for genetic test and research. A pathologist (Ahn S)
performed additional review of each case to confirm
diagnosis and select the tumors. The patients included
27 men (17%) and 132 women (83%) with a mean age of
48 years (range, 17–76 years). The mean tumor size was
0.76 cm (range, 0.1-6.5 cm).
DNA extraction and BRAF mutant cell line
Genomic DNA was extracted from two 4 μm thick sec-
tions of FFPE tumor blocks under microscopy as previ-
ously described [10] using the QIAamp DNA Mini
Kit (QIAGEN, Hilden, Ger.). The concentration and
purity of the extracted DNA were determined by a
ND-1000 spectrophotometer (NanoDrop Technologies,
Inc. Wilmington, DE, USA). The extracted DNA was
stocked at 4°C until use.
DNAs from SNU-790 cell lines were used as positive
control and normal human genomic DNAs (Roche Ap-
plied Science, Penzberg, Ger.) were used as negative
control. Serial dilutions of the positive cell line with nor-
mal human genomic DNAs to create final tumor DNA
concentrations with 100%, 50%, 25%, 12.5%, 5% and 1%
were used to compare the analytical limit of detection
(LOD).
Shifted Termination Assay (STA) fragment analysis
Applied Biosystems® BRAF mutation analysis reagents
assays were used for detection of three different BRAF
variants (V600E, V600A, and V600G) (Applied Biosystems,
CA, USA). The manufacturer’s protocol was followed
for the amplification of DNA, clean-up of PCRproducts, and primer extension reactions. After primer
extension, capillary electrophoresis and fragment ana-
lysis were performed. PCR reactions were performed
in 30 μL volumes using template DNA, BRAF PCR
primers, and DNA amplification master mix. PCR was
performed using a C1000 (Bio-Rad, CA, USA) and PCR
cycling conditions were a 5 minute hold at 94°C,
followed by 35 cycles of 94°C for 30 seconds, 52°C for
45 seconds, 72°C for 45 seconds, and 72°C for 5 mi-
nutes. After PCR, labeled PCR tubes were cleaned up,
and 2 μL of the labeled products were mixed with 9.5
μL of HiDi-formamide and 0.5 μL of Genescan SD-130
size standard. The products were separated using a 40
minute run on an ABI Prism 3130 DNA sequencer with
POP7 matrix and injection 14 seconds injection time.
GeneMapper software, version 4.1 (Applied Biosystems)
was used for analysis of the data.
Polymerase chain reaction (PCR) and direct sequencing
The mutational analyses of BRAF exon 15 were
performed by direct sequencing of PCR products ampli-
fied from genomic DNA, as previously described [10].
PCR was performed in a 20 μL volume containing 100
ng of template DNA, 10х PCR buffer; 0.25 mM dNTPs,
10 pmol primers, and 1.25 U Taq DNA polymerases
(iNtRON, Korea). Bi-directional sequencing was performed
using the BigDye Terminator v1.1 kit (Applied Biosystems)
on an ABI 3130 genetic analyzer (Applied Biosystems).
Sequencher version 4.10.1 (Gene Codes Corporation, Ann
Arbor, MI, USA) was used along with manual chromato-
gram reviews. The results were considered mutation-
positive if a mutation was detected in both the forward and
reverse DNA strands.
Statistical analysis
Statistical analyses were performed using SPSS statis-
tical software version 19.0 (SPSS, Inc., Chicago, IL,
USA). The level of agreement between genotyping fin-
dings by different methods was determined with kappa
(κ) statistics. Genotyping results were considered con-
cordant in cases of sequence agreement between assays
and discordant in cases where no genotype similarity
was observed. A p value of <0.05 was considered statis-
tically significant.
Results
In STA fragment analysis, BRAF mutation was detected
in 119 (74.8%) PTCs and all mutations were V600E.
After serial dilutions of BRAF mutant cell line, LOD of
STA fragment analysis was 6%. By direct sequencing,
BRAF V600E mutations were found in 118 (74.2%)
cases and LOD was 12.5%. The correlation between
STA-fragment analysis and direct sequencing was
strong (p < 0.00001) and a high level of agreement was




V600E Mutant 118 1 κ, 0.98(95 % CI, 0.98 to 0.99)
wild type 0 40
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one case showed discrepant result; a BRAF mutation
detected by STA fragment analysis was not detected by
direct sequencing. Pathologic review of this discrepant
case showed extrathyroidal extension and lymph node
metastasis in spite of its small size (0.6 cm) (Figure 1).
The clinicopathological characteristics of patients with
BRAF V600E mutation detected by direct sequencing
are described in Table 2. In PTCs with pT3/T4 stages,
BRAF mutation was observed in 83.8% of cases. In pT1/
T2 carcinomas, BRAF mutation was detected in 65.9%
and this difference was statistically significant (p = 0.007).
Moreover, BRAF mutation was more common in PTCs with
extrathyroidal invasion than PTCs without extrathyroidal
invasion (84.7% versus 62.2%, p = 0.001). However,
BRAF mutation was not significantly associated with
patients’ age, tumor size and lymph node metastasis
(p > 0.05).
To estimate time and costs for each method, we esti-
mated them from the preparative step to the final inter-
pretation of results. As 3130 ABI sequencer in our
laboratory is a 16-channel model, we calculated the sam-
ple size at 16. STA fragment analysis required 4 hours
and 50 minutes while direct sequencing took 7 hoursFigure 1 A papillary thyroid carcinoma with discrepant BRAF mutatio
(A) Pathology showing extrathyroidal extension. (B) BRAF mutation detecte
for BRAF mutation.and 30 minutes. To run 16 samples, STA fragment ana-
lysis costs 34$ and direct sequencing requires 25$.
Discussion
In PTCs, BRAF mutation is an important prognostic
marker. To detect BRAF mutation, direct sequencing
has been widely accepted as the gold standard. However,
this technique requires rather expensive equipment, can
be laborious and time consuming. To be applicable in
many clinical laboratories with limited equipments, di-
verse testing methods are required to detect BRAF mu-
tations. For this purpose, we first tested STA fragment
analysis to detect BRAF V600 mutation in 159 PTCs
obtained from FFPE tissue samples and found that STA
fragment analysis is as sensitive as direct sequencing and
can be easily applicable with lower costs and less run-
ning time. Moreover, BRAF mutation was associated
with extrathyroidal extension and advanced tumor stage
in PTCs.
BRAF is the strongest activator in the downstream of
MAP kinase signaling. In PTCs, the prevalence of BRAF
mutation has been variable among different studies and
its association with clinicopathological features was con-
troversial. Recently, systematic review and meta-analysesn results in STA fragment analysis and direct sequencing.
d by STA fragment analysis. (C) Sequencing result showing wild-type
Table 2 Clinicopathologic characteristics in 159 patients
with papillary thyroid carcinoma
BRAF V600E mutation P
valueCharacteristic Positive Negative
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http://www.diagnosticpathology.org/content/8/1/121on PTC showed that BRAF mutation is significantly
associated with recurrence, lymph node metastasis,
extrathyroidal extension and advanced tumor stages
[2-4]. In medullary thyroid carcinoma, RET oncogene
mutation correlates with a worse outcome [11]. In this
study, although we failed to find the relationship be-
tween BRAF mutation and lymph node metastasis, we
confirmed that BRAF mutation is closely associated with
extrathyroidal extension and advanced tumor stage.
In our previous study on BRAF mutations using very
highly sensitive dual-priming oligonucleotide-PCR and
mutant enrichment with 3′-modified oligonucleotideTable 3 Summary of literature reviews on BRAF mutation ana
Journal (references) Year Organ Tissu
Present study 2012 Thyroid FFPE and
J Mod Diagn [19] 2012 Lung and colon FFPE and
PLOS One [20] 2011 Brain FFP
Eur J Endocrinol [21] 2011 Thyroid fresh ti
PLOS One [8] 2011 Lung Cytology a
J Mod Diagn [22] 2011 Colon FFP
Clin Chim Acta [9] 2011 Skin FFP
J Mod Diagn [14] 2011 Colon FFP
Hum Pathol [4] 2010 Thyroid FFP
Genes Chromosomes Cancer 2010 Skin FFPsequencing in 4,585 consecutive cases in fine needle as-
piration cytology specimens, BRAF mutation was not
significantly associated with pT stage, extrathyroidal ex-
tension and lymph node metastasis [12]. In the present
study, although the numbers of cases are small, we
found that BRAF mutation was significantly associated
with extrathyroidal extension and advanced tumor stages
using the FFPE PTC tissue samples and standard
method to detect BRAF mutations. These results are
consistent with previous observations [2-4].
In order to be applicable in clinical laboratories, the
diagnostic assay should address several issues related to
the LOD, affordability, turnaround time and running
costs. A variety of methods have been applied for BRAF
mutations. PCR-based screening methods such as SNaP-
shot assays, AS-PCR, COLD-PCR, Taqman® SNP assay,
pyrosequencing and HRM analysis have been applied
and the commonly used methods in pathology laborator-
ies are summarized in Table 3 [13-18]. Although direct
sequencing of PCR products is the gold standard for
BRAF mutation detection in routine diagnostics, it re-
mains laborious, time consuming and requires rather ex-
pensive equipment [5,6]. In this study, we compared
LOD, total operation time and costs for the detection of
BRAF mutation between STA fragment analysis and dir-
ect sequencing. STA fragment analysis cannot detect
BRAF mutations outside the targeted codon although
direct sequencing can detect mutations located outside
targeted codon. However, in PTCs, BRAF V600E is the
most common hot spot mutation and was the only mu-
tation found in 159 PTCs in this study. In our study, one
PTC with small size (0.6 cm) and wild-type in direct se-
quencing turned out to harbor BRAF V600E mutation
by STA fragment analysis. The LOD using a BRAF mu-
tant cell line also showed higher sensitivity compared to
direct sequencing. In cases with small carcinomas, a
more sensitive assay is required to detect rare mutations.
In this context, although the numbers of examined caseslyses in recent publications
e No. of cases Methods
cell line 159 STA fragment analysis, direct sequencing
cell line 152 HRM-sequencing and HRM-SNaPshot
E 97 SNaPshot
ssues 90 Real-time PCR
nd FFPE 447 and 42 Real-time PCR
E 42 Multiplex SNaPshot
E 45 COLD-PCR
E 125 Real-time PCR
E 76 RFLP
E 116 conventional PCR
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http://www.diagnosticpathology.org/content/8/1/121are small, STA fragment analysis is a sensitive method to
detect V600 BRAF mutation and needs shorter running
time and lower costs compared to direct sequencing.
In clinical laboratories performing MSI analyses by
fluorescent PCR-based method using an ABI PRISM®
3100, STA fragment analysis can be used as an easily
applicable, rapid and cost effective method to detect
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